

Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer

Information for the public

Published: 17 November 2021

www.nice.org.uk

Nivolumab (Opdivo) is available on the NHS. It is a possible treatment for completely resected oesophageal or gastro-oesophageal junction cancer in adults if residual disease was present after neoadjuvant chemoradiotherapy.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS website](#) may be a good place to find out more.

These organisations can give you advice and support:

- [GUTS UK](#), 020 7468 0341
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-4337-1